CA2557301A1 - Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease - Google Patents
Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease Download PDFInfo
- Publication number
- CA2557301A1 CA2557301A1 CA002557301A CA2557301A CA2557301A1 CA 2557301 A1 CA2557301 A1 CA 2557301A1 CA 002557301 A CA002557301 A CA 002557301A CA 2557301 A CA2557301 A CA 2557301A CA 2557301 A1 CA2557301 A1 CA 2557301A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- group
- alkyl
- hcv
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(C)C(C(C1=O)=O)=C1N(C)C[C@@](C(C)(C)C)NC(N[C@@](C(C)(C)C)C(N(C[C@@](C1)*(C)C)[C@@]1C(NC(CC1CC1)C(C(N*)=O)=O)=O)=O)=O Chemical compound CC(C)C(C(C1=O)=O)=C1N(C)C[C@@](C(C)(C)C)NC(N[C@@](C(C)(C)C)C(N(C[C@@](C1)*(C)C)[C@@]1C(NC(CC1CC1)C(C(N*)=O)=O)=O)=O)=O 0.000 description 2
- NTUBTQQUFMODES-QHSCAFSZSA-N CC(C)(C)[C@@H](CNC(C1=O)=C(C2CC2)C1=O)NC(N[C@@H](C(C)(C)C)C(N(CC1)C(C(NC(CC2CCC2)C(C(N)=O)=O)=O)C1=[F](C)C)=O)=O Chemical compound CC(C)(C)[C@@H](CNC(C1=O)=C(C2CC2)C1=O)NC(N[C@@H](C(C)(C)C)C(N(CC1)C(C(NC(CC2CCC2)C(C(N)=O)=O)=O)C1=[F](C)C)=O)=O NTUBTQQUFMODES-QHSCAFSZSA-N 0.000 description 1
- UPWXQYRODBSCDQ-BJYQXZSCSA-N CC(C)C[C@@H](CC1)[C@@H](C(NCC(C(NC)=O)=O)=O)N1C([C@H](C(C)(C)C)NC(N[C@H](CNC(C(C1=O)=O)=C1N(C)C)C(C)(C)C)=O)=O Chemical compound CC(C)C[C@@H](CC1)[C@@H](C(NCC(C(NC)=O)=O)=O)N1C([C@H](C(C)(C)C)NC(N[C@H](CNC(C(C1=O)=O)=C1N(C)C)C(C)(C)C)=O)=O UPWXQYRODBSCDQ-BJYQXZSCSA-N 0.000 description 1
- RFYBHBJEITZLDH-IPTNVUIUSA-N CC(C)[C@H](C[C@H]1C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)CN1C([C@H](C1CCCCC1)NC(N[C@H](CN(C)C(C(C1=O)=O)=C1N(C)C)C1CCCCC1)=O)=O Chemical compound CC(C)[C@H](C[C@H]1C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)CN1C([C@H](C1CCCCC1)NC(N[C@H](CN(C)C(C(C1=O)=O)=C1N(C)C)C1CCCCC1)=O)=O RFYBHBJEITZLDH-IPTNVUIUSA-N 0.000 description 1
- GYCSZGRZZMAWPH-SANXVGBMSA-N CCCC(C(C(NCC=C)=O)=O)NC([C@H](C[C@H](C1)/C(/C)=C/C)N1C([C@H](C1CCCCC1)NC(N[C@H](CN(C)C(C1=O)=C(C2(C)CC2)C1=O)C(C)(C)C)=O)=O)=O Chemical compound CCCC(C(C(NCC=C)=O)=O)NC([C@H](C[C@H](C1)/C(/C)=C/C)N1C([C@H](C1CCCCC1)NC(N[C@H](CN(C)C(C1=O)=C(C2(C)CC2)C1=O)C(C)(C)C)=O)=O)=O GYCSZGRZZMAWPH-SANXVGBMSA-N 0.000 description 1
- XSDRDPJXSVKKQN-HBAIKHLUSA-N CCCC(C(C(NCC=C)=O)=O)NC([C@H]([C@H](CC1)C(C)C)N1C([C@H](C(C)(C)C)NC(N[C@H](CCCC(CC)C(C1=O)=C(C)C1=O)C(C)(C)C)=O)=O)O Chemical compound CCCC(C(C(NCC=C)=O)=O)NC([C@H]([C@H](CC1)C(C)C)N1C([C@H](C(C)(C)C)NC(N[C@H](CCCC(CC)C(C1=O)=C(C)C1=O)C(C)(C)C)=O)=O)O XSDRDPJXSVKKQN-HBAIKHLUSA-N 0.000 description 1
- ZDFFDVBMVFQQOP-MYWVDXEWSA-N CCNC(C(C(CC1CC1)NC([C@H]1N(C[C@H](C(C)(C)C)NC(N[C@H](CN(C)C(C(C2=O)=O)=C2N(C)C)C(C)(C)C)=O)CCC1C(C)C)=O)=O)=O Chemical compound CCNC(C(C(CC1CC1)NC([C@H]1N(C[C@H](C(C)(C)C)NC(N[C@H](CN(C)C(C(C2=O)=O)=C2N(C)C)C(C)(C)C)=O)CCC1C(C)C)=O)=O)=O ZDFFDVBMVFQQOP-MYWVDXEWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54842304P | 2004-02-27 | 2004-02-27 | |
| US60/548,423 | 2004-02-27 | ||
| PCT/US2005/006083 WO2005085197A1 (en) | 2004-02-27 | 2005-02-24 | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2557301A1 true CA2557301A1 (en) | 2005-09-15 |
Family
ID=34919362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002557301A Abandoned CA2557301A1 (en) | 2004-02-27 | 2005-02-24 | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1742914A1 (https=) |
| JP (1) | JP2007525521A (https=) |
| CN (1) | CN1946690A (https=) |
| CA (1) | CA2557301A1 (https=) |
| WO (1) | WO2005085197A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| JP2008545748A (ja) * | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| WO2006130554A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
| PL2468724T3 (pl) | 2006-12-21 | 2016-05-31 | Zealand Pharma As | Synteza związków pirolidynowych |
| US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| CN102271699A (zh) | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
| CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
| JP6989864B2 (ja) | 2017-05-05 | 2022-02-03 | ジーランド ファーマ，アー／エス | ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168103A (en) * | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| SK742003A3 (en) * | 2000-07-21 | 2003-06-03 | Schering Corp | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CN1498224A (zh) * | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| WO2002062761A1 (en) * | 2001-02-07 | 2002-08-15 | Abbott Laboratories | Aminal diones as potassium channel openers |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| PL208928B1 (pl) * | 2001-04-16 | 2011-06-30 | Pharmacopeia | 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny |
-
2005
- 2005-02-24 CN CNA2005800126511A patent/CN1946690A/zh active Pending
- 2005-02-24 EP EP05723791A patent/EP1742914A1/en not_active Withdrawn
- 2005-02-24 WO PCT/US2005/006083 patent/WO2005085197A1/en not_active Ceased
- 2005-02-24 CA CA002557301A patent/CA2557301A1/en not_active Abandoned
- 2005-02-24 JP JP2007501006A patent/JP2007525521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1946690A (zh) | 2007-04-11 |
| EP1742914A1 (en) | 2007-01-17 |
| WO2005085197A1 (en) | 2005-09-15 |
| JP2007525521A (ja) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1939213B1 (en) | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| EP1737821B1 (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| EP1773868B1 (en) | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease | |
| US7635694B2 (en) | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| EP1730165A1 (en) | Inhibitors of hepatitis c virus ns3 protease | |
| CA2557304A1 (en) | Ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus | |
| EP1748983A2 (en) | Compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| CA2549167A1 (en) | Inhibitors of hepatitis c virus ns3/ns4a serine protease | |
| EP1730110A1 (en) | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| CA2557301A1 (en) | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009809A (en) | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| HK1118066B (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| HK1095837B (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009812A (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| HK1095820B (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009815A (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009811A (en) | Compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009814A (en) | Inhibitors of hepatitis c virus ns3 protease | |
| HK1099028B (en) | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20130225 |